



Viscera Labs Announces the Preclinical Investigation of Colesevelam Targeted Delivery

PARSIPPANY, NJ – August 10, 2020 – Viscera Labs, Inc. today announced that the University of Newcastle (Newcastle, Australia) will undertake the preclinical investigation of Viscera Labs' proprietary formulation of colesevelam targeted delivery (CTD).

Laureate Professor Nicholas Talley and Professor Simon Keely of the Faculty of Health and Medicine, the University of Newcastle, will initiate preclinical investigations of CTD to assess its *in vitro* concentration response and *in vivo* dose efficacy.

Published studies suggest that bile acid sequestrants may have clinical utility in bile acid-mediated conditions such as bile acid malabsorption-diarrhea¹. However, existing formulations of bile acid sequestrants are suboptimal and hence inadequate for these conditions. Viscera Labs is developing CTD to improve the efficacy, safety, and tolerability of colesevelam in bile acid-mediated conditions.

References

1. Beigel F, et al. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study. *J Crohns Colitis*. 2014 Nov; 8(11): 1471-9.

About Viscera Labs

Viscera Labs is a preclinical stage development company that focuses on identifying novel uses for existing compounds in gastroenterology.

About the University of Newcastle

Built on the principles of equity, excellence and engagement, the University of Newcastle has a reputation as a world-class institution making an impact within its own region, throughout Australia and across the globe. Its research is world-class and diverse. Its degree programs are internationally recognized and its partnerships and collaborations drive innovation.